Astrocytic tumors account for 42% of childhood brain tumors, arising in all anatomical regions
and associated with neurofibromatosis type 1 (NF1) in 15%. Anatomical site determines …

PURPOSE Late anthrocycline cardiotoxicity after treatment for childhood cancer is common
and often progressive. A safe anthracycline dose that will not result in late cardiac …

Background KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive
disease with 3-year event-free survival below 40%. Most relapses occur during treatment…

The first (2017) and sixth (2021) multistakeholder Paediatric Strategy Forums focused on
anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. ALK is an important …

Background To identify predictors for health‐related quality of life (HRQOL) in survivors of
childhood brain tumors and its relationship to cognitive function. Procedure One hundred …

The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen
receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells …

Rapid evaluation and subsequent regulatory approval of new drugs are critical to improving
survival and reducing long-term side-effects for children and adolescents with cancer. The …

BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade
glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial …

This phase 1 study investigated the recommended phase 2 dose (RP2D) of inotuzumab
ozogamicin (InO), a CD22-directed antibody-drug conjugate, in pediatric patients with multiple …

Background Controversy exists as to what may be defined as standard of care (including
markers for stratification) for patients with atypical teratoid/rhabdoid tumors (ATRTs). The …